Parechovirus A3 (PeV-A3)-associated myalgia/myositis occurs irrespective of its genetic cluster: a longitudinal molecular epidemiology of PeV-A3 in Yamagata, Japan between 2003 and 2016

Mizuta, Katsumi; Aoki, Yoko; Komabayashi, Kenichi; Tanaka, Shizuka; Yamakawa, Tatsushi; Shimizu, Yasuyuki; Itagaki, Tsutomu; Katsushima, Fumio; Katsushima, Yuriko; Ikeda, Tatsuya

doi:10.1099/jmm.0.000894

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PeVA3, in particular, is a major cause of sepsis-like illness and central nervous infections in infants, whereas PeVA1 causes asymptomatic to mild symptomatic infections [1]. Our previous studies revealed that PeVA3 also causes epidemic myalgia in both adults and children, although this disease has not been reported from countries other than Japan to date [17, 18].…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Mizuta

Komabayashi

Aoki

et al. 2020

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

Introduction. Although new parechovirus A (PeVA) types, including parechovirus A3 (PeVA3) and PeVA4, have been reported in this century, there have not yet been any seroepidemiological studies on PeVA over a period of several decades. Hypothesis/Gap Statement. The authors hypothesize that PeVA3 and PeVA4 emerged recently. Aims. The aim was to clarify changes in the seroprevalence of PeVA1, PeVA3 and PeVA4. Methodology. Neutralizing antibodies (NT Abs) were measured among residents in Yamagata, Japan in 1976, 1983, 1985, 1990, 1999 and 2017. Results. The total NT Ab-positive rate for PeVA1 was between 90.7 and 100 % for all years analysed, with that for PeVA3 increasing from 39.6 % in 1976 to 69.6 % in 2017, and that for PeVA4 decreasing from 93.9 % in 1976 to 49.1 % in 2017. The distribution of NT Ab titres for PeVA1, PeVA3 and PeVA4 among those aged less than 20 years old was as follows: those ≥1 : 32 for PeVA1 were between 68.0–89.2 % for all years analysed; those ≥1 : 32 for PeVA3 was 15.4 % in 1976, 44.3–54.9 % in 1983–1990 and 64.8–68.0 % in 1999–2017; and those ≥1 : 32 for PeVA4 were between 49.1–67.2 % in 1976–1990, 41.3 % in 1999 and 23.8 % in 2017. Conclusions. Our findings in this seroepidemiological study over four decades suggested that PeVA1 has been stably endemic, while PeVA3 appeared around 1970s and has spread since then as an emerging disease, and occasional PeVA4 infections were common in 1970s and 1980s but have been decreasing for several decades in our community.

show abstract

Section: Introductionmentioning

confidence: 99%

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Mizuta

Komabayashi

Aoki

et al. 2020

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 However, BACM has also been associated with other viral infections as influenza A, parainfluenza, Coxsackie virus, herpes simplex virus, Epstein-Barr virus, and adenovirus infection. 3,17 Associations with rarer etiological agents, such as Parechovirus A3 (PeV-A3), responsible for myalgia and epidemic myositis in both children and adults, 18 rotavirus and norovirus, 19 and M. pneumonia infection, 20 have been described in the literature. In the group of 25 BACM children reported by Tekin and Akoğlu 21 the most common signs were walking difficulty and muscle tenderness, and pain on the gastrocnemius muscles.…”

Section: Discussionmentioning

confidence: 99%

Benign Acute Childhood Myositis: Our Experience on Clinical Evaluation

et al. 2022

View full text Add to dashboard Cite

Background. Benign Acute Childhood Myositis (BACM) is a transient condition mainly affecting children of school-age characterized by muscle pain, typically localized to the calf muscle with symmetrical lower extremity pain and difficulty in walking. Usually the clinical picture is preceded by a viral infection including influenza, parainfluenza, rotavirus and mycoplasma. Methods. The case-series was conducted in 4 pediatric hospitals in Catania, Italy, over a 12-year observational period. Clinical examination, laboratory data, course, treatment, and complications of the affected children were extracted from electronic medical records of each hospital. Results. For the case-series, fifty children diagnosed with BACM were enrolled: the mean age of affected children was 5.35 years, 86% of were males and in 56% the affections occurred during the winter. In the affected children, the clinical picture was characterized by previous fever and/or symptoms of inflammation of the upper airways, and followed by pain in the lower extremities up to uncoordinated gait. In 17 cases the etiological agent was isolated. In all the children the muscular symptomatology had a good evolution with progressive marked reduction of pain and of the high level of CKemia. Neither clinical recurrences nor sequelae were reported. Conclusions. BACM shows to have in most of the cases a favorable evolution, a spontaneous remission of symptoms and a good prognosis. It is worthy a rapid and early diagnosis in order to avoid unnecessary diagnostic investigations and a careful follow up necessary to exclude persistence of symptoms or CK elevation.

show abstract

“…We also carried out a seroepidemiological study on PeV-A1, PeV-A3, and PeV-A6 using Yamagata isolates (52). We hope that the mechanism of the disease will be resolved, the situation regarding the prevalence of this disease abroad will be known well, and laboratory diagnostic techniques for PeV-A3 will be developed and made generally available (50,53).…”

Section: -2 Proposal Of a New Disease Concept Pev-a3associated Myamentioning

confidence: 99%

Longitudinal Epidemiology of Viral Infectious Diseases Combining Virus Isolation, Antigenic Analysis, and Phylogenetic Analysis as Well as Seroepidemiology in Yamagata, Japan, between 1999 and 2018

et al. 2019

Self Cite

View full text Add to dashboard Cite

Parechovirus A3 (PeV-A3)-associated myalgia/myositis occurs irrespective of its genetic cluster: a longitudinal molecular epidemiology of PeV-A3 in Yamagata, Japan between 2003 and 2016

Cited by 6 publications

References 21 publications

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017

Benign Acute Childhood Myositis: Our Experience on Clinical Evaluation

Longitudinal Epidemiology of Viral Infectious Diseases Combining Virus Isolation, Antigenic Analysis, and Phylogenetic Analysis as Well as Seroepidemiology in Yamagata, Japan, between 1999 and 2018

Contact Info

Product

Resources

About